Drug Trial Radar · NCT04400318
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
Last checked: Nov 20, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
109
Actual
Start
Jun 20, 2020
Primary completion
Jun 26, 2023
Study completion Aug 21, 2023
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- May 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: • To assess the effect of dupilumab on lung inflammation and related changes in airway volumes detectable by functional respiratory imaging Secondary Objective: * To evaluate the effect of dupilumab at Week 24 on bronchodynamics, hyperinflation, airway resistance, airway wall thickness, ventilation defects and mucus plugging derived from high-resolution computed tomography (HRCT) scans, patient-reported outcomes, FeNO and spirometry. * To evaluate safety of dupilumab
Conditions
- Asthma
Interventions
DupilumabDrug
solution for injection subcutaneous
PlaceboDrug
Solution for injection subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved Fractional Exhaled Nitric Oxide (FeNO) Less Than (<) 25 Parts Per Billion (Ppb) at Week 24Time frame: Week 24
- Percent Change From Baseline to Week 24 in Untrimmed Distal Specific Airway Volumes ([s]iVaw) at Total Lung Capacity (TLC)Time frame: Baseline (Day 1) to Week 24
Locations
65 sites in 13 countries. Site status is shown where the registry gives one.
Allianz Research Institute Site Number : 8400020
Westminster, California
University of Kansas School of Medicine Site Number : 8400008
Kansas City, Kansas
University of Michigan Site Number : 8400002
Ann Arbor, Michigan
The Lung Research Center Site Number : 8400010
Chesterfield, Missouri
American Health Research Site Number : 8400005
Charlotte, North Carolina
Velocity Clinical Research, Medford Site Number : 8400014
Medford, Oregon
Medical University of South Carolina - Pulmonary & Critical Care Clinical Research Program Site Number : 8400009
Charleston, South Carolina
VitaLink Research-Greenville Site Number : 8400013
Greenville, South Carolina
VitaLink Research - Spartanburg Site Number : 8400011
Spartanburg, South Carolina
~Spartanburg Medical Research Site Number : 8400004
Spartanburg, South Carolina
Investigational Site Number : 1000013
Dupnitsa, Bulgaria
Investigational Site Number : 1000004
Montana, Bulgaria
Investigational Site Number : 1000018
Plovdiv, Bulgaria
Investigational Site Number : 1000012
Plovdiv, Bulgaria
Investigational Site Number : 1000008
Rousse, Bulgaria
Investigational Site Number : 1000015
Sofia, Bulgaria
Investigational Site Number : 1000005
Sofia, Bulgaria
Investigational Site Number : 1000003
Sofia, Bulgaria
Investigational Site Number : 1000006
Sofia, Bulgaria
Investigational Site Number : 1000011
Sofia, Bulgaria
Investigational Site Number : 1000010
Sofia, Bulgaria
Investigational Site Number : 1000002
Sofia, Bulgaria
Investigational Site Number : 1000007
Stara Zagora, Bulgaria
Investigational Site Number : 2080006
Aarhus N, Denmark
Investigational Site Number : 2080002
Copenhagen, Denmark
Investigational Site Number : 2080003
Copenhagen Nv, Denmark
Investigational Site Number : 2080001
Hvidovre, Denmark
Investigational Site Number : 2500001
Montpellier, France
Investigational Site Number : 3800001
Pisa, Italy
Investigational Site Number : 3800003
Cona, Ferrara, Italy
Investigational Site Number : 3800004
Rozzano, Milano, Italy
Investigational Site Number : 6200004
Coimbra, Portugal
Investigational Site Number : 6200005
Guimarães, Portugal
Investigational Site Number : 6200006
Lisbon, Portugal
Investigational Site Number : 6200003
Porto, Portugal
Investigational Site Number : 6200001
Porto, Portugal
Investigational Site Number : 6420005
Bragadiru, Romania
Investigational Site Number : 6420008
Brasov, Romania
Investigational Site Number : 6420006
Cluj-Napoca, Romania
Investigational Site Number : 6420001
Cluj-Napoca, Romania
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.